Cargando…
Evolution of the Role of Radiotherapy for Anal Cancer
SIMPLE SUMMARY: Prior to the 1980s, primary management of localized anal cancer was surgery. Dr. Norman Nigro and colleagues found that neoadjuvant chemoradiotherapy with 5-fluorouracil and mitomycin C afforded complete response, obviating the need for surgery upfront. Advancements in radiotherapy d...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001637/ https://www.ncbi.nlm.nih.gov/pubmed/33801992 http://dx.doi.org/10.3390/cancers13061208 |
_version_ | 1783671276804505600 |
---|---|
author | Dee, Edward Christopher Byrne, James D. Wo, Jennifer Y. |
author_facet | Dee, Edward Christopher Byrne, James D. Wo, Jennifer Y. |
author_sort | Dee, Edward Christopher |
collection | PubMed |
description | SIMPLE SUMMARY: Prior to the 1980s, primary management of localized anal cancer was surgery. Dr. Norman Nigro and colleagues found that neoadjuvant chemoradiotherapy with 5-fluorouracil and mitomycin C afforded complete response, obviating the need for surgery upfront. Advancements in radiotherapy delivery using intensity-modulated radiation therapy (IMRT) and image-guided radiation have resulted in reductions in radiation-associated adverse effects, allowing for the delivery of greater doses of radiation. Ongoing prospective trials are attempting to improve IMRT-based treatment of locally advanced disease with efforts to increase personalized treatment. Trials of newer modalities such as proton therapy are underway. In this review, we present the evolution of radiotherapy for anal cancer and describe recent advances to contextualize ongoing studies and inform future directions in efforts to mitigate treatment toxicities, further personalize treatment, and improve oncologic outcomes. ABSTRACT: Prior to the 1980s, the primary management of localized anal cancer was surgical resection. Dr. Norman Nigro and colleagues introduced neoadjuvant chemoradiotherapy prior to abdominoperineal resection. Chemoradiotherapy 5-fluorouracil and mitomycin C afforded patients complete pathologic response and obviated the need for upfront surgery. More recent studies have attempted to alter or exclude chemotherapy used in the Nigro regimen to mitigate toxicity, often with worse outcomes. Reductions in acute adverse effects have been associated with marked advancements in radiotherapy delivery using intensity-modulated radiation therapy (IMRT) and image-guidance radiation delivery, resulting in increased tolerance to greater radiation doses. Ongoing trials are attempting to improve IMRT-based treatment of locally advanced disease with efforts to increase personalized treatment. Studies are also examining the role of newer treatment modalities such as proton therapy in treating anal cancer. Here we review the evolution of radiotherapy for anal cancer and describe recent advances. We also elaborate on radiotherapy’s role in locally persistent or recurrent anal cancer. |
format | Online Article Text |
id | pubmed-8001637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80016372021-03-28 Evolution of the Role of Radiotherapy for Anal Cancer Dee, Edward Christopher Byrne, James D. Wo, Jennifer Y. Cancers (Basel) Review SIMPLE SUMMARY: Prior to the 1980s, primary management of localized anal cancer was surgery. Dr. Norman Nigro and colleagues found that neoadjuvant chemoradiotherapy with 5-fluorouracil and mitomycin C afforded complete response, obviating the need for surgery upfront. Advancements in radiotherapy delivery using intensity-modulated radiation therapy (IMRT) and image-guided radiation have resulted in reductions in radiation-associated adverse effects, allowing for the delivery of greater doses of radiation. Ongoing prospective trials are attempting to improve IMRT-based treatment of locally advanced disease with efforts to increase personalized treatment. Trials of newer modalities such as proton therapy are underway. In this review, we present the evolution of radiotherapy for anal cancer and describe recent advances to contextualize ongoing studies and inform future directions in efforts to mitigate treatment toxicities, further personalize treatment, and improve oncologic outcomes. ABSTRACT: Prior to the 1980s, the primary management of localized anal cancer was surgical resection. Dr. Norman Nigro and colleagues introduced neoadjuvant chemoradiotherapy prior to abdominoperineal resection. Chemoradiotherapy 5-fluorouracil and mitomycin C afforded patients complete pathologic response and obviated the need for upfront surgery. More recent studies have attempted to alter or exclude chemotherapy used in the Nigro regimen to mitigate toxicity, often with worse outcomes. Reductions in acute adverse effects have been associated with marked advancements in radiotherapy delivery using intensity-modulated radiation therapy (IMRT) and image-guidance radiation delivery, resulting in increased tolerance to greater radiation doses. Ongoing trials are attempting to improve IMRT-based treatment of locally advanced disease with efforts to increase personalized treatment. Studies are also examining the role of newer treatment modalities such as proton therapy in treating anal cancer. Here we review the evolution of radiotherapy for anal cancer and describe recent advances. We also elaborate on radiotherapy’s role in locally persistent or recurrent anal cancer. MDPI 2021-03-10 /pmc/articles/PMC8001637/ /pubmed/33801992 http://dx.doi.org/10.3390/cancers13061208 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Dee, Edward Christopher Byrne, James D. Wo, Jennifer Y. Evolution of the Role of Radiotherapy for Anal Cancer |
title | Evolution of the Role of Radiotherapy for Anal Cancer |
title_full | Evolution of the Role of Radiotherapy for Anal Cancer |
title_fullStr | Evolution of the Role of Radiotherapy for Anal Cancer |
title_full_unstemmed | Evolution of the Role of Radiotherapy for Anal Cancer |
title_short | Evolution of the Role of Radiotherapy for Anal Cancer |
title_sort | evolution of the role of radiotherapy for anal cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001637/ https://www.ncbi.nlm.nih.gov/pubmed/33801992 http://dx.doi.org/10.3390/cancers13061208 |
work_keys_str_mv | AT deeedwardchristopher evolutionoftheroleofradiotherapyforanalcancer AT byrnejamesd evolutionoftheroleofradiotherapyforanalcancer AT wojennifery evolutionoftheroleofradiotherapyforanalcancer |